CD34 and Miyoshi myopathy: In its pivotal phase III trial in 302 patients with MM, the plerixafor group showed a higher rate of successful collection (CD34+ cells of 6 × 106/kg or greater) compared to the placebo group (71.6% vs. 34.4%; p < 0.001) [12].